Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JAMA Oncology

• Publication date

  2017-11-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jamaoncol.2017.2085PMID 28750133PMCID PMC5824197
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.

  2017cited by this paper
• MARIANNE: Impact on Current Treatment of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Implications for the Future.

  2017cited by this paper
• RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial

  2017cited by this paper
• Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.

  2016cited by this paper
• Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group

  2016cited by this paper
• A perspective on anti-EGFR therapies targeting triple-negative breast cancer.

  2016cited by this paper
• Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication

  2016cited by this paper
• Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

  2016cited by this paper
• Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.

  2016cited by this paper
• Therapeutics Targeting FGF Signaling Network in Human Diseases.

  2016cited by this paper
• Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group

  2016cited by this paper
• Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review.

  2016cited by this paper
• Relevance of tumor-infiltrating lymphocytes in breast cancer

  2015cited by this paper
• Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

  2015cited by this paper
• Are immune signatures a worthwhile tool for decision making in early-stage human epidermal growth factor receptor 2-positive breast cancer?

  2015cited by this paper
• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

  2015cited by this paper
• Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

  2015cited by this paper
• Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade

  2015cited by this paper
• Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.

  2015cited by this paper
• Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.

  2015cited by this paper
• The clinical and functional significance of c-Met in breast cancer: a review

  2015cited by this paper
• Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration

  2014cited by this paper
• Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients.

  2014cited by this paper
• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

  2014cited by this paper
• The immune system and response to HER2-targeted treatment in breast cancer.

  2014cited by this paper
• Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy

  2013cited by this paper
• Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.

  2013cited by this paper
• Molecular Pathways Molecular Pathways : Involvement of ImmunePathways in the Therapeutic Response and Outcome in Breast Cancer

  2012cited by this paper
• CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer

  2012cited by this paper
• Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

  2012cited by this paper
• Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

  2012cited by this paper
• Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer

  2011cited by this paper
• Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy

  2011cited by this paper
• Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

  2011cited by this paper
• Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade

  2011cited by this paper
• CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes

  2011cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

  2010cited by this paper
• Use of archived specimens in evaluation of prognostic and predictive biomarkers.

  2009cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

  1999cited by this paper
• Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

  1998cited by this paper

• Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges

  2025cites this paper
• Unraveling the molecular-pathological characteristics and cellular complexity of the tumor immune microenvironment in metastatic non-small cell lung cancer

  2025cites this paper
• Prognostic and predictive capacity of tumor infiltrating lymphocytes in the MA.20 regional node radiotherapy trial

  2025cites this paper
• Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment

  2025cites this paper
• Clinical implications of peripheral blood biomarkers in patients with advanced breast cancer treated with trastuzumab emtansine and trastuzumab deruxtecan

  2025cites this paper
• Interaction between redox regulation, immune activation, and response to treatment in HER2+ breast cancer

  2025cites this paper
• Dynamic changes in serum adenosine and the adenosine metabolism-based signature for prognosis in HER2-positive metastatic breast cancer patients

  2024cites this paper
• Immune microenvironment heterogeneity of concurrent adenocarcinoma and squamous cell carcinoma in multiple primary lung cancers

  2024cites this paper
• Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Prognostic and Predictive Significance across Molecular Subtypes

  2024influential citation
• B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer

  2023cites this paper
• Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment

  2023cites this paper
• CD47 and CD68 expression in breast cancer is associated with tumor‐infiltrating lymphocytes, blood vessel invasion, detection mode, and prognosis

  2023cites this paper
• Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist’s Perspective

  2023cites this paper
• Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes

  2022cites this paper
• Prognostic value of CD8+ tumor-infiltrating T cells in patients with breast cancer: A systematic review and meta-analysis

  2022cites this paper
• Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer

  2022cites this paper
• Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody–Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis

  2022cites this paper
• Immunological Landscape of HER-2 Positive Breast Cancer

  2022cites this paper
• Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial

  2022cites this paper
• Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer

  2022cites this paper
• Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes

  2022cites this paper
• Tumor‐associated lymphocytes and macrophages are related to stromal elastosis and vascular invasion in breast cancer

  2021cites this paper
• Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications

  2021cites this paper
• Exercise Training Improves Tumor Control by Increasing CD8+ T-cell Infiltration via CXCR3 Signaling and Sensitizes Breast Cancer to Immune Checkpoint Blockade

  2021cites this paper
• HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now

  2021cites this paper
• The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine

  2021cites this paper
• Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer

  2021cites this paper
• The journey of tumor infiltrating lymphocytes (TIL) as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.

  2021cites this paper
• Human Epidermal Growth Factor Receptor Type 2-Positive Breast Cancer: Association of MRI and Clinicopathologic Features With Tumor-Infiltrating Lymphocytes.

  2021cites this paper
• Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer

  2021cites this paper
• Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy

  2021cites this paper
• Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer

  2021influential citation
• The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

  2021cites this paper
• Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial

  2020cites this paper
• The prognostic role of tumor-infiltrating lymphocytes in urothelial carcinoma of bladder: A systematic review and meta-analysis

  2020cites this paper
• Tumor-infiltrating lymphocytes and the PD-L1/PD-1 signaling axis in breast cancer: biology and clinical implications

  2020cites this paper
• Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies

  2020cites this paper
• Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer.

  2020cites this paper
• More efficient use of HER targeting agents in cancer therapy

  2019cites this paper
• Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm

  2019cites this paper
• Monoklonale Antikörper

  2019cites this paper
• Low number of intrafollicular T cells may predict favourable response to rituximab-based immuno-chemotherapy in advanced follicular lymphoma: a secondary analysis of a randomized clinical trial

  2019cites this paper
• Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy.

  2019cites this paper
• Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer

  2019cites this paper
• Precision cytopathology: expanding opportunities for biomarker testing in cytopathology.

  2019cites this paper
• NHERF 1 Between Promises and Hopes : Overview on Cancer and Prospective Openings 1

  2018cites this paper
• NHERF1 Between Promises and Hopes: Overview on Cancer and Prospective Openings

  2018cites this paper
• A machine learning method for subgroup analysis of randomized controlled trials

  2018cites this paper
• T lymphocyte subsets in cancer immunity: Friends or foes

  2018cites this paper
• Immune characterization of breast cancer metastases: prognostic implications

  2018cites this paper